Abstract
AbstractCorneal damage due to different circumstances such as chemical injuries, cicatrizing immune‐based keratoconjunctivitis, severe dry eye disease (graft vs host disease mainly), sequelae of infections, repeated ocular surgeries or congenital disorders (such as congenital aniridia) affects the integrity of the corneal epithelium, being an important cause of visual impairment and blindness that affects millions of people worldwide Mesenchymal stem cells (MSC) and its derivatives represent a readily available, non‐immunogenic source of stem cell that has a great amount of regenerative and anti‐inflammatory properties. For these reasons, MSC have emerged as very attractive candidates for cell‐based therapies in numerous and diverse clinical applications including the treatment of ocular surface diseases such as limbal stem cell deficiency, dry eye disease, or even as a potential therapy to improve corneal allograft survival. Although part of the current preclinical evidence has already been successfully translated into the clinical evidence field, work must continue to overcome all the scientific and the technical challenges that still need to be solved. This presentation summarizes the main preclinical and clinical evidence that encouragingly supports MSC‐based therapies as safe and effective treatments for the regeneration of the ocular surface.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
